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Introduction: Hypoxia and hypercapnia are closely linked to morbidity and mortality in patients with Cystic Fibrosis (CF). The aims of this study
were to describe the changes in blood gases during and following an acute pulmonary exacerbation in adults with CF.
Methods: We performed a prospective observational study of patients with CF admitted for management of an acute exacerbation. Blood gas and
spirometric analysis was performed on admission, throughout the treatment period, and 31 days after discharge (day 45).
Results: At presentation, eight of nineteen patients had evidence of either hypoxia (PaO2b8 kPa) and/or hypercapnia (PaCO2N6.6 kPa). Blood
gas parameters stabilized following two weeks of intravenous antibiotic therapy, with little difference evident in between treatment completion and
subsequent review following discharge. Hypercapnia reversed in three patients, with persistent hypercapnia evident in two patients.
Conclusion: In our study group, hypoxemia and hypercapnia were frequently observed at presentation of the acute exacerbation. Blood gases
stabilized following two weeks of intravenous antibiotic therapy, with arterial PCO2 one month following hospital discharge generally similar to
that at time of discharge.
© 2008 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: Arterial blood gas; Cystic Fibrosis; Hypercapnia; Hypoxia; Pulmonary exacerbation1. Introduction
Survival of patients with Cystic Fibrosis (CF) has greatly
improved over the past three decades [1] due to the aggressive
treatment of pulmonary disease [2], the close monitoring of
nutritional status[3,4] and the development of specialized CF
centers [5]. However, despite these advances, the majority of
morbidity and mortality in patients with CF remains related to
pulmonary disease, with pulmonary failure accounting for 85%
of deaths amongst the CF population [6,7]. Death in patients
with CF is preceded by progressive deterioration in pulmonary
function and gas exchange, with acute pulmonary exacerbations
closely linked to morbidity and mortality.⁎ Corresponding author. National Referral Centre for Adult Cystic Fibrosis,
St. Vincent's University Hospital, Elm Park, Dublin 4, Ireland. Tel.: +353 1
2694533.
E-mail address: c.gallagher@st-vincents.ie (C.G. Gallagher).
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doi:10.1016/j.jcf.2008.07.001Predictors of death in patients with CF include pulmonary
hypertension related to chronic hypoxemia, hypoxemia on
admission for pulmonary exacerbations, and chronic hypercar-
bia [8–10]. However, despite the central importance of both
hypoxia and hypercapnia in patient outcome, there is very little
detailed information available concerning hypoxia and hyper-
capnia during acute pulmonary exacerbations. We performed a
prospective observational study to detail the pattern of ABG
changes during acute exacerbations, to investigate the ABG
changes following two weeks of intravenous antibiotic therapy,
and finally, to assess ABG characteristics following resolution
of the exacerbation, during a period of clinical stability.
2. Methods
We performed a prospective observational study of con-
secutive patients admitted to hospital for management of an
acute pulmonary exacerbation of CF. Upon admission (day 1),
each patient underwent clinical assessment, spirometry andd by Elsevier B.V. All rights reserved.
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45 days after admission. Following management of the acute
pulmonary exacerbation, all patients reported major improve-
ment in symptoms and, in all cases, the treating physician
concluded that the acute exacerbation had resolved at the end of
the 14 day treatment period. Notably, the data collected in this
study did not influence treatment, or duration of treatment, of
the acute exacerbation.
Patients were recruited from the inpatient department of the
National Referral Centre for Adult Cystic Fibrosis at St.
Vincent's University Hospital, Dublin. A diagnosis of CF was
confirmed based on appropriate clinical features, abnormal
sweat test (sweat Cl−N70 mmol/L) and/or genotyping [11].
Consecutive patients, with a confirmed diagnosis of CF,
hospitalized for management of an acute pulmonary exacerba-
tion, were recruited.
An acute exacerbation was diagnosed according to the
criteria published by the 1994 Cystic Fibrosis Foundation
Microbiology and Infectious Disease Consensus Conference
[12] as the presence of three or more of the following new
findings compared to the most recent visit: increased cough;
increased sputum volume, thickness or increased darkness of
sputum; increased dypsnoea, decreased exercise tolerance or
both; weight loss≥1 kg or 5% of bodyweight associated with
anorexia; fatigue; temperature greater than 38 °C for at least 4 h
in a 24 h period; 10% decrease in spirometry from best value
achieved over the previous three months; new infiltrate on chest
radiograph; school or work absenteeism due to illness in the
past week. Patients had been unwell for no longer than 3–5 days
prior to enrollment in the study.
Informed written consent was obtained from each participant
prior to enrollment and the study was approved by the Ethics
Committee of St. Vincent's University Hospital.
Upon diagnosis of an acute pulmonary exacerbation, and
prior to commencement of intravenous antibiotic therapy, each
patient had an ABG sample taken from their radial artery while
in a supine position using a 25 gauge needle after a minimum of
30 min rest breathing room air. Topical anesthetic was offered to
each patient prior to the ABG being performed to minimize
discomfort. Upon drawing 2 ml of arterial blood, the sample
was immediately analyzed for determination of PaO2, PaCO2
and pH. Standard electrode techniques (ABL 520 Radiometer,
Copenhagen, Denmark) were used.
Subsequently, each patient received the standard of care for
management of an acute pulmonary exacerbation, consisting ofTable 1
Median values for the study population throughout the study period
Variable All patients initially enrolled (n=42) Study grou
Day 1 Day 1
FEV1 (L) 0.91(0.5–3.3) 0.84(0.5–3
FEV1 % predicted 25(16–78) 23(16–73
Blood pH 7.42(7.31–7.52) 7.43(7.32–
PaO2 (kPa) 8.9(6.7–12.2) 8.6(6.7–1
PaCO2 (kPa) 5.5(4.5–8.4) 5.8(4.5–8
CRP 46(4–277) 44(4–277
Values presented as median (range).two weeks of a minimum of two intravenous antibiotics chosen
according to the sensitivity of the bacteria isolated from previous
sputum sample [13], nebulised antibiotics, bronchodilators as
well as daily physiotherapy and nutritional support [14].
Further ABGs were taken throughout the treatment period on
day 7, day 14 and one month after completion of the inpatient
course during a period of clinical stability (day 45). Clinical
stability was defined as no change in medication dosage or
frequency and no exacerbations of disease or hospital admission
in the preceding four weeks. ABGs were obtained at the same
time of day on each occasion to control for circadian variations.
For interpretation of the ABG results, hypercapnia was defined
as PaCO2 greater than 6.6 kPa (50 mmHg) [15,16]. Hypoxemia
was defined as PaO2 less than 8 kPa (60 mmHg) [17].
Forced vital capacity (FVC) and forced expiratory volume in
one second (FEV1) were assessed according to the American
Thoracic Guidelines [18] using a spirometer (Vitalograph
Compact II, Fannin, Ireland). Spirometry was performed with
the patient in a seated position. Calibration of the spirometer
was performed prior to each examination to ensure accuracy of
reading.
Finally, C-reactive protein (CRP) was measured on days 1, 7,
14 and 45 using standard techniques.
3. Statistical analysis
All data was recorded on Microsoft Excel spreadsheets while
statistical analysis was performed using a computerized
statistical package (SPSS version 11, SPSS Inc 1989–2001,
Chicago, Illinois, USA). The data is presented as median and
range unless otherwise stated. The Mann Whitney U test was
used to compare variables for evidence of statistically
significant differences between the groups. A relationship was
considered statistically significant if pb0.05.
4. Results
Of the 42 patients initially approached to take part, 23 did not
complete the study. The reasons for noncompletion of the study
were declining further ABGs (n=21) and self discharge from
hospital prior to completion of study protocol (n=2). This left a
cohort of 19 patients which forms our study group (12 males
(63%) and 7 females (37%)).
Median age for the study cohort was 24 years (range 19–
45 years). The median baseline FEV1, defined as the best FEV1p (n=19)
Day 7 Day 14 Day 45
.25) 0.88(0.53–3.66) 0.96(0.65–3.45) 1.08(0.71–3.76)
) 26(16–83) 30(17–78) 32(20–81)
7.52) 7.42(7.33–7.45) 7.42(7.30–7.47) 7.42(7.37–7.46)
2.2) 9.2(5.9–12.7) 9.4(6.5–12.4) 10.6(7.2–12.2)
.4) 5.9(4.75–9.21) 5.6(4.26–7.23) 5.3(4.80–7.12)
) 22(4–335) 11(4–49) 6(4–26)
Fig. 1. Sequential changes in PaO2 for the studied population (n=19).
Fig. 3. Evolution of PaCO2 for hypercapnic and non-hypercapnic patient groups
throughout treatment period.
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preceding six months, was 1.1 (range 0.9 to 3.7) L. Nutritional
status was widely variable, with body mass index (BMI)
ranging from normal (BMI 25) to significantly malnourished
(BMI 17.3) with a median BMI of 20.2.
Table 1 illustrates the median ABG values for the study
population throughout the treatment period and during subse-
quent review following discharge (n=19). Additionally, admis-
sion data for all subjects initially enrolled is illustrated (n=42).
Four patients were hypoxic on admission, the median PaO2
for the four hypoxic patients being 7.5 kPa (6.7–7.9 kPa).
Within 7 days of therapy, most hypoxic patients had notable
improvement in their oxygenation, with median PaO2 for the
hypoxic patient group rising to 8.35 kPa (5.9–9.1) on day 7 and
9.35 kPa (6.5–12.4) on day 14. When reviewed following
discharge from hospital, this improvement in oxygenation was
maintained with median PaO2 9.55 kPa (7.2–10.8). Fig. 1
illustrates the sequential changes in PaO2 for the studied
population (n=19) throughout the study period.
Five patients were hypercapnic on admission. Median
presentation PaCO2 for the hypercapnic patients was 7.81 kPa
(6.89–8.36). Some individuals experienced an initial rise in
PaCO2 at day 7, however median PaCO2 for the hypercapnic
group fell to 6.89 kPa (5.74–9.21) on day 7, and 6.16 kPaFig. 2. Sequential changes in PaCO2 for the studied population (n=19).(5.51–7.23) at treatment completion. When reviewed in the
outpatients department on day 45, median PaCO2 for the
hypercapnic patient group remained stable with a median of
6.23 kPa (4.84–7.12). By day 45, hypercapnia had reversed in
three patients with two patients found to be chronically
hypercapnic. Fig. 2 illustrates the sequential changes in
PaCO2 for the studied population.
When compared to those patients whose PaCO2 at admission
was within normal limits, patients presenting with hypercapnia
had both a lower baseline FEV1 % predicted (27(22–33) vs.
39.5(22–85), p=0.05) and admission FEV1 % predicted (17.5
(16–23) vs. 25(17–73), p=0.11). There were no significant
differences in age (p=0.55), BMI (p=0.07) or admission PaO2
(p=0.68) between the hypercapnic and the normocapnic patient
groups. Within the hypercapnic patient group, mean PaCO2 fell
throughout the treatment period, however, for the normocapnic
group, PaCO2 remained essentially stable throughout the study
period (Fig. 3).
Eleven patients were neither hypoxic nor hypercapnic on
admission. No patients had evidence of hypocapnic (PaCO2b
4.27 kPa) on admission.
Four patients had metabolic alkalosis on admission
(pHN7.45, with normal range PaCO2). PaCO2 remained stable
following treatment completion (between day 14 and day 45),
suggesting that PaCO2 at successful completion of intravenous
therapy may be used as a guide to PaCO2 during clinically
stable disease.Fig. 4. Sequential changes in FEV1 for the studied population (n=17).
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significantly from baseline levels (pb0.0002). Fig. 4 illustrates
the initial fall in median FEV1 at admission (n=17) from
baseline levels and subsequent progressive improvement
throughout the treatment period.
5. Discussion
This study found that 42% of adults with CF admitted for
treatment of a pulmonary exacerbation had hypoxia and/or
hypercapnia. Following 14 day treatment with enhanced airway
clearance and intravenous antibiotics, hypercapnia reversed in
all but 2 patients. Arterial PCO2 one month following hospital
discharge was generally similar to that at time of discharge.
In this study, hypoxiawas evident in four patients at admission,
with subsequent improvement in oxygenation throughout the
study period following management of the acute exacerbation. In
three of these patients, the hypoxia had improved by day 7 of
treatment, indicating a relatively rapid resolution of this clinical
state. Notably, no patients had focal infiltrates on Chest X-Ray.
Hypoxia, the major reason for pulmonary hypertension in CF,
may have been due to ventilation/perfusion mismatch and, in
some patients, hypoventilation.
We have demonstrated a substantial risk of hypercapnia in
CF patients during acute pulmonary exacerbations of their
disease, with hypercapnia evident in 26% of the studied
population at exacerbation presentation. These findings may
have significant clinical implications. Stable hypercapnia, in
particular a PaCO2N6.6 kPa (50 mm Hg), is associated with a
poor prognosis in patients with CF 9 and is considered to be an
indication for noninvasive ventilatory support, particularly in
patients who are awaiting transplantation [19]. Previous studies
have shown that hypercapnia is more likely to develop in those
with an FEV1 less than 60% [20]. This study supports these
findings with hypercapnic patients having a median baseline
FEV1 of 0.9 L (27% of predicted) and a median FEV1 at
admission of 0.68 L (17.5% predicted). However, some recent
work suggests that mortality in CF is poorly reflected by FEV1
[21–23].
Episodic hypoxemia and hypercapnia can occur in CF
patients during times of physiologic stress such as during REM
sleep [24,25] and, to a lesser extent, during exercise [26,27].
Furthermore, a high prevalence of reversible hypercapnia has
shown to occur during exacerbations of COPD [28]. Previously,
Wagener et al. have demonstrated similar blood gas patterns
amongst CF and COPD patients [29]. This study demonstrates
reversible hypercapnia in some CF patients following success-
ful management of their acute exacerbation. Moreover, when
compared, reversible hypercapnic and chronic hypercapnic
patients had similar admission PaCO2 levels, indicating that
some patients who are normocapnic when clinically stable may
develop similar levels of hypercapnia during exacerbations as
those with chronic hypercapnia. Therefore, the likelihood of
developing chronic hypercapnia cannot be predicted from the
severity of hypercapnia at exacerbation presentation. These
findings are supported by previous work in patients with
COPD.37 Notably however, patients who were shown to bechronically hypercapnic had lower admission FEV1 and a
greater fall from baseline than those in whom hypercapnia
reversed, suggesting that reversible patients have milder disease
and/or experience a milder exacerbation than those in whom
chronic hypercapnia develops.
While the size of the cohort who completed the study was
small, the nineteen patients who completed the study had
similar admission blood gases, FEV1 and CRP to the twenty-
three additional subjects who were initially enrolled but failed to
complete the study. We thus believe our study population is
representative and reflects the range of blood gas changes in CF
patients with acute pulmonary exacerbations.
In conclusion, the findings of this study indicate that
hypoxemia and hypercapnia are frequently observed among
adult patients with CF presenting with an acute pulmonary
exacerbation of their disease. Furthermore, arterial PCO2 at time
of discharge was generally similar to that one month following
hospital discharge.
Acknowledgements
Supported by grants from the Health Research Board and the
Cystic Fibrosis Association of Ireland. The authors are very
grateful to the patients for participating in this research.References
[1] Elborn JS, Shale DJ, Briton JR. Cystic fibrosis: current survival and
population estimates to the year 2000. Thorax 1991;46:881–5.
[2] Yankaskas JR, Marshall BC, Sufian B, Simon RH, Rodman D. Cystic
fibrosis adult care consensus report. Chest 2004;125:1S–39S.
[3] Turck D. Cystic fibrosis: nutritional consequences and management.
Baillieres Clin Gastroentero 1998;12(4):805–22.
[4] Kraemer R. Relative underweight in cystic fibrosis and its prognostic
value. Acta Paediatr Scand 1978;67(1):33–7.
[5] FitzSimmons SC. The changing epidemiology of cystic fibrosis. J Pediatr
1993;122:1–9.
[6] Morgan WJ, Butler SM, Johnson CA, Colin AA, FitzSimmons SC, Geller
DE, et al. Epidemiologic Study of Cystic Fibrosis. Pediatr Pulmonol
1999;28:231–41.
[7] Davis PB. Clinical pathophysiology and manifestations of lung disease. In:
Yankaskas JR, Knowles M, editors. Cystic fibrosis in adults. 1st ed.
Philadelphia: Lippincott-Raven; 1999. p. 45–67.
[8] Ellaffi M, Vinsonneau C, Coste J, Hubert D, Burgel PR, Dhainaut JF, et al.
One-year outcome after severe pulmonary exacerbation in adults with
cystic fibrosis. Am J Respir Crit Care Med 2005;171(2):158–64.
[9] Eckles M, Anderson P. Cor pulmonale in cystic fibrosis. Semin Respir Crit
Care Med 2003;24(3):323–30.
[10] Kerem E, Reisman J, Corey M, Canny GJ, Levison H. Prediction
of mortality in patients with cystic fibrosis. N Engl J Med 1992;326:
1187–91.
[11] Rosenstein BJ, Cutting JR. The diagnosis of CF: a consensus statement:
Cystic Fibrosis Foundation Consensus Panel. J Pediatr 1998;132:589–95.
[12] Cystic Fibrosis Foundation. Microbiology and infectious disease in
cystic fibrosis. V (Section 1). Bethesda: Cystic Fibrosis Foundation;
1994. p. 1–26.
[13] Aaron SD, Ramotar K, Ferris W, Vandemheen K, Saginur R, Tullis E, et al.
Adult cystic fibrosis exacerbations and new strains of Pseudomonas
aeruginosa. Am J Respir Crit Care Med 2004;169(7):811–5.
[14] Schidlow D, Taussig L, Knowles M. Cystic Fibrosis Foundation
Consensus Conference report on pulmonary complications of cystic
fibrosis. Pediatr Pulmonol 1993;15:187–98.
13D.F. Waterhouse et al. / Journal of Cystic Fibrosis 8 (2009) 9–13[15] American Thoracic Society. Standards for the diagnosis and care of
patients with chronic obstructive pulmonary disease. Am J Respir Crit
Care Med 1995;152(5 Pt 2):S77–S121.
[16] Pauwels RA, Buist AS, Calverley PM, Jenkins CR, Hurd SS. GOLD
Scientific Committee. Global strategy for the diagnosis, management, and
prevention of chronic obstructive pulmonary disease. NHLBI/WHO
Global Initiative for Chronic Obstructive Lung Disease (GOLD) Work-
shop summary. Am J Respir Crit Care Med 2001;163(5):1256–76.
[17] Campbell EJ. Respiratory failure. Br Med J 1965;5448:1451–60.
[18] American Thoracic Society. Standardization of spirometry, 1994 update.
Am J Respir Crit Care Med 1995;152(3):1107–36.
[19] Hill AT, Edenborough FP, Cayton RM, Stableforth DE. Long-term nasal
intermittent positive pressure ventilation in patients with cystic fibrosis and
hypercapnic respiratory failure (1991–1996). Respir Med 1998;92:523–6.
[20] Cropp GJ, Pullano TP, Cerny FJ, Nathanson IT. Exercise tolerance and
cardiorespiratory adjustments at peak work capacity in cystic fibrosis. Am
Rev Respir Dis 1982;126(2):211–6.
[21] Robinson W, Waltz DA. FEV(1) as a guide to lung transplant referral in
young patients with cystic fibrosis. Pediatr Pulmonol 2000;30
(3):198–202.
[22] Liou TG, Adler FR, Cahill BC, FitzSimmons SC, Huang D, Hibbs JR, et al.
Survival effect of lung transplantation among patients with cystic fibrosis.
JAMA 2001;286(21):2683–9.[23] Mayer-Hamblett N, Rosenfeld M, Emerson J, Goss CH, Aitken ML.
Developing cystic fibrosis lung transplant referral criteria using predictors
of 2-year mortality. Am J Respir Crit Care Med 2002;166(12 Pt
1):1550–5.
[24] Tepper RS, Skatrud JB, Dempsey J. Ventilation and oxygen changes
during sleep in cystic fibrosis. Chest 1983;84:388–93.
[25] Spier S, Rivlin J, Hughes D, Levison H. The effect of oxygen on sleep,
blood gases, and ventilation in cystic fibrosis. Am Rev Respir Dis
1984;121:463–9.
[26] Bradley S, Solin P, Wilson J, Johns D, Walters EH, Naughton MT.
Hypoxemia and hypercapnia during exercise and sleep in patients with
cystic fibrosis. Chest 1999;116(3):647–54.
[27] Javadpour SM, Selvadurai H, Wilkes DL, Schneiderman-Walker J, Coates
AL. Does carbon dioxide retention during exercise predict a more rapid
decline in FEV1 in cystic fibrosis? Arch Dis Child 2005;90(8):792–5.
[28] McNally E, Fitzpatrick M, Bourke S, Costello R, McNicholas WT.
Reversible hypercapnia in acute exacerbations of chronic obstructive
pulmonary disease. Eur Respir J 1993;6:1353–6.
[29] Wagener D, et al. Comparison of lung function and survival patterns
between cystic fibrosis and emphysema or chronic bronchitis patients. In:
Sturgess JM, editor. Perspectives in cystic fibrosis, Ontario. Canada:
Imperial Press Ltd; 1980. p. 236–45.
